Division of Infectious Diseases and Immunology Research

At NYU Langone’s Division of Infectious Diseases and Immunology, we believe that research is the engine that drives new medical advances to protect and restore public health locally and globally. Research is an important part of our mission, and our goal is to translate scientific research into innovative ways to prevent, diagnose, and treat infectious diseases.
Our research activities cover the entire span of biomedical discovery—from preclinical laboratory research using animal models, to clinical studies and clinical trials that translate into clinical practice. We also conduct research on healthcare policy, education, and behavior.
We are dedicated to training the next generation of research leaders in the field of infectious diseases and immunology. Important research initiatives within our division include the Vaccine Center, NYU Langone Molecular Outbreak Program, Special Pathogens Program at NYC Health + Hospitals/Bellevue, and hepatitis C elimination studies, as well as research on Staphylococcus aureus bacteria, hepatitis B, influenza, universal flu vaccine, flaviviruses, and yellow fever virus vaccines.
Core Faculty Investigators
Benjamin J. Eckhardt, MD
Assistant Professor, Department of Medicine
Lead Investigator, Hepatitis C Elimination Studies
Ramin Herati, MD
Assistant Professor, Department of Medicine
Mark J. Mulligan, MD
Director, Division of Infectious Diseases and Immunology
Director, Vaccine Center
The Thomas S. Murphy Sr. Professor, Department of Medicine
Bo Shopsin, MD, PhD
Associate Director, Research, Division of Infectious Diseases
Director, Molecular Epidemiology Director, Antimicrobial-Resistant Pathogens
Program Associate Director of MSTP Curriculum and Programming
Associate Professor, Department of Microbiology
Scott A. Weisenberg, MD
Medical Director, NYU Langone Infectious Disease Associates
Medical Director, Travel Medicine Program
Clinical Associate Professor, Department of Medicine
Faculty Publications
Our faculty publish their research in leading peer-reviewed journals. Learn more about their recent publications.
Mucosal and Systemic Antibody Responses After Boosting With a Bivalent Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine
The Journal of infectious diseases. 2025 Apr 29;
Sex-dependent gastrointestinal colonization resistance to MRSA is microbiota and Th17 dependent
eLife. 2025 Apr 08; 13:
A Phase 1/2 Randomized Study to Evaluate the Safety, Tolerability, and Immunogenicity of Nucleoside-Modified Messenger RNA Influenza Vaccines in Healthy Adults
Vaccines. 2025 Apr 03; 13:
Providers' Perspectives on Implementation of Low-threshold HCV Treatment in New York State: A Qualitative Study
Open forum infectious diseases. 2025 Apr ; 12:ofaf184
The two-dose MVA-BN mpox vaccine induces a nondurable and low avidity MPXV-specific antibody response
Journal of virology. 2025 Mar 31; e0025325
Enterobacter hormaechei replaces virulence with carbapenem resistance via porin loss
Proceedings of the National Academy of Sciences of the United States of America (PNAS). 2025 Feb 25; 122:e2414315122
Does PCR-based pathogen identification reduce mortality in bloodstream infections? Insights from a difference-in-difference analysis
Infection control & hospital epidemiology. 2025 Feb 14; 1-7
System vaccinology analysis of predictors and mechanisms of antibody response durability to multiple vaccines in humans
Nature immunology. 2025 Jan ; 26:116-130